Skip to main content
. 2019 Aug 20;10(49):5011–5019. doi: 10.18632/oncotarget.27082

Figure 4. Effects of TAK228 in combination with chemotherapy in vivo.

Figure 4

PTEN loss PDX BCX.024 (A) and BCX.055 (B) were treated with TAK228 and a variety of chemotherapeutic agents to screen for potential combination therapies (n = 2-3). (C) BCX.024 and (D) BCX.100 xenografts were treated with vehicle (n = 5; n = 4), TAK228 1 mg/kg daily (n = 5; n = 4), eribulin 0.3 mg/kg weekly (n = 5; n = 5) or TAK228 in combination with eribulin (n = 4; n = 4). Values are presented as mean ± SEM of tumor volume. P-value shown are multiple comparisons test on final day of possible comparison.